Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis

Modern Pathology

Volumn 28, Issue 7, 2015, Pages 895-903

  Jahn, Stephan W ^a   Kashofer, Karl ^a   Halbwedl, Iris ^a   Winter, Gerlinde ^a   El Shabrawi Caelen, Laila ^a   Mentzel, Thomas ^b   Hoefler, Gerald ^a   Liegl Atzwanger, Bernadette ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Dermatopathologie Bodensee   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ADULT; AGED; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MALE; MELANOMA; MIDDLE AGED; MUTATION; PATHOLOGY; SKIN TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SKIN NEOPLASMS;

EID: 84934440220     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.39     Document Type: Article

References (48)

1. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971;28:914-936.
2. McCarthy SW, Scolyer RA, Palmer AA. Desmoplastic melanoma: a diagnostic trap for the unwary. Pathology 2004;36:445-451.
3. Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol 2005;12:92-102.
4. Chen JY, Hruby G, Scolyer RA et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008;113:2770-2778.
5. Jaroszewski DE, Pockaj BA, DiCaudo DJ et al. The clinical behavior of desmoplastic melanoma. Am J Surg 2001;182:590-595.
6. George E, McClain SE, Slingluff CL et al. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol 2009;36:425-432.
7. Pawlik TM, Ross MI, Prieto VG et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 2006;106: 900-906.
8. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
9. Le K, Blomain ES, Rodeck U et al. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res 2013;26:509-517.
10. Curtin JA, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-4346.
11. Fullen DR, Poynter JN, Lowe L et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol 2006;19:1324-1332.
12. Ellerhorst JA, Greene VR, Ekmekcioglu S et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011;17:229-235.
13. Sasaki Y, Niu C, Makino R et al. BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 2004;123:177-183.
14. Goel VK, Lazar AJ, Warneke CL et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006;126:154-160.
15. Saldanha G, Potter L, Daforno P et al. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 2006;12: 4499-4505.
16. Wong CW, Fan YS, Chan TL et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 2005;58:640-644.
17. Edmunds SC, Cree IA, Di Nicolantonio F et al. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 2003;88:1403-1405.
18. Van Raamsdonk CD, Griewank KG, Crosby MB et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-2199.
19. Griewank KG, van de Nes J, Schilling B et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Mod Pathol 2014;27:175-183.
20. Edwards RH, Ward MR, Wu H et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 2004;41:270-272.
21. Davison JM, Rosenbaum E, Barrett TL et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005;103:788-792.
22. Coupelon S, Franck F, Jarrousse AS et al. Desmoplastic malignant melanoma: a study of ten cases and status of BRAF mutation. Dermatology 2012;225:168-171.
23. Miller DD, Emley A, Yang S et al. Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal. Mod Pathol 2012;25: 505-515.
24. Kim J, Lazar AJ, Davies MA et al. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 2012;39:821-825.
25. Narita N, Tanemura A, Murali R et al. Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 2009;28:3058-3068.
26. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001;12: 361-373.
27. Sawai H, Okada Y, Kazanjian K et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 2005;65:11536-11544.
28. Barr J, Amato CM, Robinson SE et al. The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma. Melanoma Res 2012;22:92-95.
29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
30. Cingolani P, Platts A, Wang le L et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012;6:80-92.
31. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-1081.
32. Forbes SA, Beare D, Gunasekaran P et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43: D805-D811.
33. Kiuru M, McDermott G, Berger M et al. Desmoplastic melanoma with sarcomatoid dedifferentiation. Am J Surg Pathol 2014;38:864-870.
34. Rosenberg JE, Bambury RM, Van Allen EM et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs 2014;32:178-187.
35. Kan Z, Jaiswal BS, Stinson J et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010;466:869-873.
36. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-813.
37. Guo G, Sun X, Chen C et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;45: 1459-1463.
38. Greaves WO, Verma S, Patel KP et al. Frequency and spectrum of BRAF mutations in a retrospective, singleinstitution study of 1112 cases of melanoma. J Mol Diagn 2013;15:220-226.
39. Wei X, Walia V, Lin JC et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011;43:442-446.
40. Vries RG, Bezrookove V, Zuijderduijn LM et al. Cancerassociated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev 2005;19:665-670.
41. Lin H, Wong RP, Martinka M et al. Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin Cancer Res 2009;15:6404-6411.
42. Krauthammer M, Kong Y, Ha BH et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-1014.
43. Tartaglia M, Martinelli S, Cazzaniga G et al. Genetic evidence for lineage-related and differentiation stagerelated contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004;104:307-313.
44. Van Raamsdonk CD, Bezrookove V, Green G et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
45. Populo H, Vinagre J, Lopes JM et al. Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol 2011;95: 715-719.
46. Safaee Ardekani G, Jafarnejad SM, Tan L et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012;7:e47054.
47. Niu HT, Zhou QM, Wang F et al. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. Pigment Cell Melanoma Res 2013;26:646-653.
48. Glatz-Krieger K, Pache M, Tapia C et al. Anatomic sitespecific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. Virchows Arch 2006;449: 328-333.